EUVIMEDEUVIMED entdecken
Crossref

Exposure to the immune system during bridging radiotherapy for Car-T cells

Pierre Loap, Justine Decroocq, Rudy Birsen, Natacha Johnson, Didier Bouscary, Youlia Kirova

Cancer/Radiothérapie · 2025

DOI: 10.1016/j.canrad.2025.104595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer/Radiothérapie, 2025. Verfasst von Pierre Loap und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Radiation Oncology, institut Curie, Paris, France; Laboratoire d'imagerie translationnelle en oncologie (Lito), institut Curie, Orsay,…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Immune System, Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The objective of this study was to quantify how much dose from bridging radiotherapy is being delivered to non-lymphoma immune cells. MATERIAL AND METHODS: All patients who underwent bridging radiotherapy between January 2023 and April 2024 at the institut Curie (Paris, France) surrounding the infusion of chimeric antigen receptor (Car)-T cells, were identified. The effective dose to the immune cells was calculated for each of them. RESULTS: Nine patients were included, with a mean follow-up time of 6months; one patient experienced a recurrence. No grade 2+ toxicity was reported. Median effective dose to the immune cells was 0.56Gy (range: 0.039-2.72Gy) and varied between patients. The main contribution came from the integral dose (0.43Gy, range: 0.039-1.42Gy). CONCLUSIONS: The doses received by the immune system when undergoing bridging radiotherapy for Car-T cells can vary considerably from one patient to another, and the integral dose represents the primary part of this exposure of the immune system. Prospective solid data is needed in this context to evaluate the role of choice of radiotherapy techniques in bridging radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenImmune SystemNeoplasmsHumansMiddle AgedMaleFemaleAgedRadiotherapy DosageAdultRetrospective StudiesT-Lymphocytes

Stichwörter der Autor:innen

Bridging radiotherapyCellules immunitairesCellules immunitaires non lymphomateusesEDICNon-lymphoma immune cellsRadiothérapie de transition

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Departement of Radiation Oncology, institut Curie, Paris, France; Laboratoire d'imagerie translationnelle en oncologie (Lito), institut Curie, Orsay, France.
  • Department of Haematology, hôpital Cochin, Paris, France.
  • Departement of Radiation Oncology, institut Curie, Paris, France. Electronic address: youlia.kirova@curie.fr.

Zitieren

APA

Loap, P., Decroocq, J., Birsen, R., Johnson, N., Bouscary, D., & Kirova, Y. (2025). Exposure to the immune system during bridging radiotherapy for Car-T cells. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2025.104595

Vancouver

Loap P, Decroocq J, Birsen R, Johnson N, Bouscary D, Kirova Y. Exposure to the immune system during bridging radiotherapy for Car-T cells. Cancer/Radiothérapie. 2025. doi:10.1016/j.canrad.2025.104595

BibTeX
@article{Loap2025,
  author = {Loap, Pierre and Decroocq, Justine and Birsen, Rudy and Johnson, Natacha and Bouscary, Didier and Kirova, Youlia},
  title = {Exposure to the immune system during bridging radiotherapy for Car-T cells},
  journal = {Cancer/Radiothérapie},
  year = {2025},
  doi = {10.1016/j.canrad.2025.104595}
}
Kostenlos starten →